Cameron Turtle - 15 Feb 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: SYRE
Reported as of: 15 Feb 2024
Net transaction value: +$3,928
SEC form: 4
Accepted by SEC: 20 Feb 2024, 21:21:33 UTC
Prior SEC filing: 02 Feb 2024
Next SEC filing: 06 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Cameron Turtle filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 20 Feb 2024.

Key facts

This page summarizes Cameron Turtle's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Feb 2024, 21:21.

Change

Previous filing in this sequence was filed on 02 Feb 2024.
Current net transaction value: +$3,928.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRE transaction

Common Stock

Award

Transaction value: $3,928
Shares: +400
Change %: +0.05%
Price: $9.82^*
Shares after: 746,907
Date: 15 Feb 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Footnote F2

Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.